Patent Ductus Arteriosus-Time for a Definitive Trial.
Anti-Inflammatory Agents, Non-Steroidal
/ therapeutic use
Bronchopulmonary Dysplasia
/ epidemiology
Conservative Treatment
Ductus Arteriosus, Patent
/ physiopathology
Enterocolitis, Necrotizing
/ epidemiology
Gestational Age
Hemodynamics
Humans
Infant, Extremely Premature
Infant, Newborn
Infant, Premature
Ligation
/ methods
Mortality
Randomized Controlled Trials as Topic
Severity of Illness Index
Treatment Outcome
Patent ductus arteriosus
Preterm infant
Randomized controlled trial
Journal
Clinics in perinatology
ISSN: 1557-9840
Titre abrégé: Clin Perinatol
Pays: United States
ID NLM: 7501306
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
entrez:
28
7
2020
pubmed:
28
7
2020
medline:
21
10
2021
Statut:
ppublish
Résumé
More than 70 randomized controlled trials have been conducted on the management of patent ductus arteriosus (PDA) in preterm infants. Yet, clinicians are unsure if treating a PDA improves clinically important outcomes. Earlier clinical trials have primarily explored which pharmacotherapeutic agent effectively closes the PDA. Because many of these trials included older infants, had widely varying PDA definitions, and provided open-label treatment, it is difficult to draw inferences on clinical outcomes based on the results of these trials. These flaws in trial design might have contributed to the growing notion that "no treatment" is a feasible option irrespective of the clinical characteristics of the infant and the PDA shunt volume.
Identifiants
pubmed: 32713454
pii: S0095-5108(20)30059-2
doi: 10.1016/j.clp.2020.05.007
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
617-639Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors have nothing to disclose.